Bajaj Healthcare Gears Up for Q3 Reveal on 15th January; Check Key Expectations Here

Name: Stock Advisory service In India
Brand: univest
Rating: 4.4 (197000 reviews)

Posted by : sachet | Thu Jan 15 2026

Bajaj Healthcare Gears Up for Q3 Reveal on 15th January; Check Key Expectations Here

Click and Sign Up to Get Live Updates on Q3 Results

Bajaj Healthcare, one of the most significant Indian conglomerates, is set to announce its Q3 results for FY26 on 15th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Bajaj Healthcare Q3 Results 2026 Preview

Bajaj Healthcare’s revenue is expected to be in the range of ₹246.99 crore, a 49.24% YoY decrease.
Profit After Tax, or PAT, is projected to fall by 130% YoY.
Bajaj Healthcare’s EBITDA is expected to rise to ₹65.86 crore.
Net profit at ₹2567.89 crore, a rise of 80% YoY

Bajaj Healthcare Share Performance

Over the past six months, Bajaj Healthcare’s share price has fallen by 9.97% to ₹287.20.
Moreover, over the past year, the stock has increased by 5.30%.
Despite this weak short-term performance, Bajaj Healthcare’s stock has delivered a financially sound 33.94% return over the past 5 years.
As of 14th January 2026, the stock traded at ₹287.30 per share.

Key Factors to Watch for Bajaj Healthcare

Revenue & Segment Growth: Growth in core businesses like APIs, formulations, intermediates, and speciality products, especially exports and high‑margin segments, which drive top‑line momentum.
Profitability & Margin Stability: Sustaining improvement in net profits and operating margins amid past volatility and competitive pricing pressures in the pharmaceutical sector.
Regulatory Approvals & Product Pipeline: Progress in clinical trials, new drug approvals, and registrations in regulated markets that can open higher‑value opportunities.
Financial Health & Debt Management: Debt levels, leverage ratios, and working capital efficiency, as ongoing deleveraging and cash‑flow improvement support long‑term stability.

Final Thoughts

Bajaj Healthcare will announce its Q3 FY26 results on 15th January 2026. Analysts expect strong revenue growth of 8% YoY, a 5.35% rise in PAT, and a 65.86% decline in EBITDA. Bajaj Healthcare focuses on developing, manufacturing, and supplying active pharmaceutical ingredients (APIs), intermediates, finished formulations, amino acids, and nutraceutical products for domestic and global pharmaceutical, nutraceutical, and food industries.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!